Catalyst Pharmaceuticals Stock Buy Hold or Sell Recommendation
| CPRX Stock | USD 21.12 0.03 0.14% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Catalyst Pharmaceuticals is 'Hold'. A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell Catalyst Pharmaceuticals given historical horizon and risk tolerance towards Catalyst Pharmaceuticals. When Macroaxis issues a 'buy' or 'sell' recommendation for Catalyst Pharmaceuticals, the advice is generated through an automated system that utilizes algorithms and statistical models.
Check out Catalyst Pharmaceuticals Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more information on how to buy Catalyst Stock please use our How to Invest in Catalyst Pharmaceuticals guide. In addition, we conduct extensive research on individual companies such as Catalyst and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Catalyst Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
Catalyst |
Execute Catalyst Pharmaceuticals Buy or Sell Advice
The Catalyst recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Catalyst Pharmaceuticals. Macroaxis does not own or have any residual interests in Catalyst Pharmaceuticals or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Catalyst Pharmaceuticals' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Hold
Market Performance | Insignificant | Details | |
Volatility | Very steady | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Very Low | Details | |
Economic Sensitivity | Almost mirrors the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Strong | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Catalyst Pharmaceuticals Trading Alerts and Improvement Suggestions
| Catalyst Pharmaceuticals has a strong financial position based on the latest SEC filings | |
| Over 82.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from news.google.com: Catalyst Pharmaceuticals to Participate in Upcoming Investor Conferences - Yahoo Finance |
Catalyst Pharmaceuticals Returns Distribution Density
The distribution of Catalyst Pharmaceuticals' historical returns is an attempt to chart the uncertainty of Catalyst Pharmaceuticals' future price movements. The chart of the probability distribution of Catalyst Pharmaceuticals daily returns describes the distribution of returns around its average expected value. We use Catalyst Pharmaceuticals price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Catalyst Pharmaceuticals returns is essential to provide solid investment advice for Catalyst Pharmaceuticals.
| Mean Return | 0.05 | Value At Risk | -2.52 | Potential Upside | 2.92 | Standard Deviation | 1.87 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Catalyst Pharmaceuticals historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Catalyst Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument, such as Catalyst Pharmaceuticals, soars without any apparent reason? This usually happens because many institutional investors are aggressively trading Catalyst Pharmaceuticals back and forth among themselves.
| Shares | Royce & Associates, Lp | 2024-09-30 | 2 M | Boston Partners Global Investors, Inc | 2024-06-30 | 1.4 M | Northern Trust Corp | 2024-09-30 | 1.4 M | Jacobs Levy Equity Management, Inc. | 2024-06-30 | 1.3 M | Kennedy Capital Management Inc | 2024-06-30 | 1.3 M | T. Rowe Price Associates, Inc. | 2024-06-30 | 1.2 M | Marshall Wace Asset Management Ltd | 2024-06-30 | 1.2 M | Charles Schwab Investment Management Inc | 2024-09-30 | 1.2 M | Goldman Sachs Group Inc | 2024-06-30 | 1.1 M | Blackrock Inc | 2024-06-30 | 18.7 M | Deerfield Management Co | 2024-06-30 | 9.1 M |
Catalyst Pharmaceuticals Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | 73.0M | 40.7M | 41.2M | 127.0M | (160.8M) | (152.7M) | |
| Free Cash Flow | 34.6M | 45.0M | 59.4M | 116.0M | (54.9M) | (52.2M) | |
| Depreciation | 297.7K | 885.3K | 192K | 1.2M | 32.9M | 34.5M | |
| Other Non Cash Items | (290.8K) | (12.2K) | 287K | 5.2M | 80.2M | 84.2M | |
| Capital Expenditures | 19.4K | 11.4K | 1.0M | 29K | 198.5M | 208.5M | |
| Net Income | 31.9M | 75.0M | 39.5M | 83.1M | 71.4M | 75.0M | |
| End Period Cash Flow | 89.5M | 130.2M | 171.4M | 298.4M | 137.6M | 144.5M | |
| Change To Inventory | (1.9M) | (2.7M) | (3.2M) | 1.1M | (4.7M) | (4.5M) | |
| Change To Netincome | 3.8M | (25.9M) | 15.4M | 12.8M | 14.8M | 15.5M | |
| Investments | 37.2M | (5.0M) | (10M) | 19.2M | (255.2M) | (242.4M) |
Catalyst Pharmaceuticals Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Catalyst Pharmaceuticals or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Catalyst Pharmaceuticals' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Catalyst stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.04 | |
β | Beta against Dow Jones | 0.98 | |
σ | Overall volatility | 1.88 | |
Ir | Information ratio | -0.02 |
Catalyst Pharmaceuticals Volatility Alert
Catalyst Pharmaceuticals has relatively low volatility with skewness of -0.09 and kurtosis of 0.53. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Catalyst Pharmaceuticals' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Catalyst Pharmaceuticals' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Catalyst Pharmaceuticals Fundamentals Vs Peers
Comparing Catalyst Pharmaceuticals' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Catalyst Pharmaceuticals' direct or indirect competition across all of the common fundamentals between Catalyst Pharmaceuticals and the related equities. This way, we can detect undervalued stocks with similar characteristics as Catalyst Pharmaceuticals or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Catalyst Pharmaceuticals' fundamental indicators could also be used in its relative valuation, which is a method of valuing Catalyst Pharmaceuticals by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Catalyst Pharmaceuticals to competition |
| Fundamentals | Catalyst Pharmaceuticals | Peer Average |
| Return On Equity | 0.28 | -0.31 |
| Return On Asset | 0.18 | -0.14 |
| Profit Margin | 0.31 % | (1.27) % |
| Operating Margin | 0.40 % | (5.51) % |
| Current Valuation | 2.08 B | 16.62 B |
| Shares Outstanding | 119.27 M | 571.82 M |
| Shares Owned By Insiders | 5.98 % | 10.09 % |
| Shares Owned By Institutions | 81.71 % | 39.21 % |
| Number Of Shares Shorted | 6.01 M | 4.71 M |
| Price To Earning | 23.62 X | 28.72 X |
| Price To Book | 3.82 X | 9.51 X |
| Price To Sales | 5.48 X | 11.42 X |
| Revenue | 398.2 M | 9.43 B |
| Gross Profit | 160.02 M | 27.38 B |
| EBITDA | 86.81 M | 3.9 B |
| Net Income | 71.41 M | 570.98 M |
| Cash And Equivalents | 220.79 M | 2.7 B |
| Cash Per Share | 2.15 X | 5.01 X |
| Total Debt | 3.56 M | 5.32 B |
| Debt To Equity | 0.02 % | 48.70 % |
| Current Ratio | 10.79 X | 2.16 X |
| Book Value Per Share | 5.54 X | 1.93 K |
| Cash Flow From Operations | 143.6 M | 971.22 M |
| Short Ratio | 8.20 X | 4.00 X |
| Earnings Per Share | 1.18 X | 3.12 X |
| Target Price | 32.25 | |
| Number Of Employees | 167 | 18.84 K |
| Beta | 0.76 | -0.15 |
| Market Capitalization | 2.52 B | 19.03 B |
| Total Asset | 470.11 M | 29.47 B |
| Retained Earnings | 121.27 M | 9.33 B |
| Working Capital | 143.27 M | 1.48 B |
| Current Asset | 59.9 M | 9.34 B |
Note: Disposition of 72500 shares by Patrick McEnany of Catalyst Pharmaceuticals at 3.54 subject to Rule 16b-3 [view details]
Catalyst Pharmaceuticals Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Catalyst . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Catalyst Pharmaceuticals Buy or Sell Advice
When is the right time to buy or sell Catalyst Pharmaceuticals? Buying financial instruments such as Catalyst Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Catalyst Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Most Shorted Equities Thematic Idea Now
Most Shorted Equities
Dynamically calculated list of top equities currently trending upward via a buy-out by investors. The Most Shorted Equities theme has 190 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Most Shorted Equities Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Catalyst Stock Analysis
When running Catalyst Pharmaceuticals' price analysis, check to measure Catalyst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Catalyst Pharmaceuticals is operating at the current time. Most of Catalyst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Catalyst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Catalyst Pharmaceuticals' price. Additionally, you may evaluate how the addition of Catalyst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.